Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Anti-CD38 antibody
Bridging therapy
CART
HSCT
VTD-PACE
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
07
2023
accepted:
29
08
2023
medline:
13
11
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Bortezomib (Velcade), thalidomide, dexamethasone, platinum (cisplatin), adriamycin (doxorubicin), cyclophosphamide, and etoposide (VTD-PACE) are commonly used as salvage treatment for patients with relapsed/refractory multiple myeloma (RRMM). However, its outcomes in the era of monoclonal antibodies remain unclear. Therefore, this retrospective cohort study assessed the clinical outcomes of 60 patients with RRMM (median four prior treatment lines) administered VTD-PACE. The median follow-up period was 11.1 months, during which they received a median of two cycles of VTD-PACE. The overall response rate (ORR) was 66.7%; ORRs of 53.1 and 82.1% were noted in patients with ≥ 4 and ≤ 3 prior lines (P = 0.027), respectively. The median overall survival (OS) was 17 months, with a median progression-free survival (PFS) of 9.8 months. Using the 3-month time point after VTD-PACE treatment as a landmark, 54 patients were still alive. Landmark analysis was conducted for PFS and OS of patients who received or did not receive HSCT or CART after VTD-PACE treatment. Patients who underwent subsequent hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T-cell therapy (CART) following VTD-PACE showed a trend of longer PFS and OS than those who did not undergo subsequent HSCT or CART. The median OS in patients with and without renal dysfunction was 10.7 months and 21.5 months, respectively (P = 0.0091). Therefore, VTD-PACE is useful as a bridging therapy for HSCT or CART, as a response can be expected regardless of organ damage, disease risk, or history of anti-CD38 antibody use.
Identifiants
pubmed: 37668787
doi: 10.1007/s00277-023-05432-x
pii: 10.1007/s00277-023-05432-x
doi:
Substances chimiques
Antibodies, Monoclonal
0
Dexamethasone
7S5I7G3JQL
Bortezomib
69G8BD63PP
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3489-3497Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ (2022) Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 387(2):132–147. https://doi.org/10.1056/NEJMoa2204925
doi: 10.1056/NEJMoa2204925
pubmed: 35660812
pmcid: 10040899
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D’Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS (2021) Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 40(25):2901–2912. https://doi.org/10.1200/jco.21.01935
doi: 10.1200/jco.21.01935
pubmed: 34898239
Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y (2023) Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol 200(6):694–703. https://doi.org/10.1111/bjh.18654
doi: 10.1111/bjh.18654
pubmed: 36661264
Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK (2018) Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol 93(2):179–186. https://doi.org/10.1002/ajh.24954
doi: 10.1002/ajh.24954
pubmed: 29067723
Togano T, Andoh S, Komuro M, Mitsui Y, Itoi S, Hirai R, Nakamura M, Tanimura A, Sekine R, Takeshita M, Miwa A, Hagiwara S (2022) Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a salvage and bridging regimen before hematopoietic stem cell transplantation for relapsed or refractory multiple myeloma. Intern Med 61(22):3329–3334. https://doi.org/10.2169/internalmedicine.9097-21
doi: 10.2169/internalmedicine.9097-21
pubmed: 35466165
pmcid: 9751732
Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC (2015) A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer 121(20):3622–3630. https://doi.org/10.1002/cncr.29533
doi: 10.1002/cncr.29533
pubmed: 26149422
Ghandili S, Alihodzic D, Wiessner C, Bokemeyer C, Weisel K, Leypoldt LB (2023) VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience. Ann Hematol 102(1):117–124. https://doi.org/10.1007/s00277-022-05027-y
doi: 10.1007/s00277-022-05027-y
pubmed: 36383242
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos M-V, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau J-L, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K (2021) DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol 192(3):e73–e77. https://doi.org/10.1111/bjh.17248
doi: 10.1111/bjh.17248
pubmed: 33236352
Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, Reece D, Stewart KA, Trieu Y, Trudel S, Chen CI (2013) D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol 161(6):802–810. https://doi.org/10.1111/bjh.12325
doi: 10.1111/bjh.12325
pubmed: 23594335
Djebbari F, De Abrew K, Salhan B, Panitsas F, Hossain MI, Eyre TA, Willan J, Ramasamy K, Basu S, Jenner M, Kothari J (2020) DPACE-based chemotherapy in the era of myeloma novel agents: a UK multicentre study. Eur J Haematol 105(2):231–233. https://doi.org/10.1111/ejh.13422
doi: 10.1111/ejh.13422
pubmed: 32268442
Huynh T, Corre E, Lemonnier MP, Duléry R, Marjanovic Z, Jaff N, Lapusan S, Mohty M, Garderet L, Coppo P (2021) Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leuk Lymphoma 62(9):2235–2241. https://doi.org/10.1080/10428194.2021.1907373
doi: 10.1080/10428194.2021.1907373
pubmed: 33792474
Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S (2021) Outcomes of VD-PACE with immunomodulatory agent as a salvage therapy for relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 21(2):e220–e226. https://doi.org/10.1016/j.clml.2020.09.002
doi: 10.1016/j.clml.2020.09.002
pubmed: 33093009
Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF (2021) KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma. Clin Lymphoma Myeloma Leuk 21(8):526–535. https://doi.org/10.1016/j.clml.2021.03.013
doi: 10.1016/j.clml.2021.03.013
pubmed: 33985931
Cowan AJ, Green DJ, Karami M, Becker PS, Tuazon S, Coffey DG, Hyun TS, Libby EN, Gopal AK, Holmberg LA (2020) KRD-PACE mobilization for multiple myeloma patients with significant residual disease before autologous stem-cell transplantation. Clin Lymphoma Myeloma Leuk 20(9):602–609. https://doi.org/10.1016/j.clml.2020.04.002
doi: 10.1016/j.clml.2020.04.002
pubmed: 32457024
D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall’Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, BladéCreixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P (2022) Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol 40(29):3406–3418. https://doi.org/10.1200/JCO.21.02614
doi: 10.1200/JCO.21.02614
pubmed: 35605179
Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J, Dytfeld D, Angelucci E, Perrot A, Benjamin R, Van De Donk NWCJ, Ocio EM, Scheid C, Gay F, Roeloffzen W, Rodriguez-Otero P, Broijl A, Potamianou A, Sakabedoyan C, Semerjian M, Keim S, Strulev V, Schecter JM, Vogel M, Wapenaar R, Nesheiwat T, San-Miguel J, Sonneveld P, Einsele H, Moreau P (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia 36(5):1371–1376. https://doi.org/10.1038/s41375-022-01531-2
doi: 10.1038/s41375-022-01531-2
pubmed: 35332278
pmcid: 9061296
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosiñol L, Usmani SZ, Zamagni E, Richardson P (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12(3):45. https://doi.org/10.1038/s41408-022-00643-3
doi: 10.1038/s41408-022-00643-3
pubmed: 35314675
pmcid: 8938478
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33(9):2266–2275. https://doi.org/10.1038/s41375-019-0435-7
doi: 10.1038/s41375-019-0435-7
pubmed: 30858549
pmcid: 6820050